RecruitingPhase 1NCT03809351

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

Sponsor

University of Alabama at Birmingham

Enrollment

160 participants

Start Date

Jul 8, 2020

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cognitive status will be the primary outcome of this imaging study. Individuals participating in this AV-1451-PET/MRI study will also be enrolled in an ongoing \[C-11\]PiB-PET/MRI study (IRB-300001005, IND-138128), and their amyloid, tau and cognitive statuses will be compared in terms of race and vascular risk factors.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This substudy is using a specialized brain scan called a tau-PET scan (which detects a harmful protein called tau that builds up in the brains of Alzheimer's patients) to better understand the early signs of Alzheimer's disease. **You may be eligible if...** - You are already enrolled in the UAB Alzheimer's Disease Center (UAB-ADC) study - You are also enrolled in the related amyloid-PET brain imaging substudy - If you are a woman of childbearing age, you must have a negative pregnancy test within 2 days of the brain scan **You may NOT be eligible if...** - You meet any exclusion criteria from the main UAB-ADC study - You are unable to have an MRI or PET scan (for example, due to metal implants or claustrophobia) - Your symptoms are too severe to lie still during the imaging Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[F-18]AV-1451-PET

All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.

Locations(1)

UAB

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03809351

Related Trials

A Study of LY3439539 in Participants With Alzheimer's Disease

NCT075983707 locations

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229255 locations